Frovatriptan

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]

Frovatriptan
Clinical data
Trade namesFrova
Other names6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
(6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
AHFS/Drugs.comMonograph
MedlinePlusa604013
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
    Routes of
    administration    		Oral
    ATC code
    Legal status
    Legal status
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Bioavailability20–30%
    MetabolismHepatic
    Elimination half-life26 hours
    ExcretionRenal
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC14H17N3O
    Molar mass243.310 g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Pharmacology

    Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. It is available as 2.5 mg tablets.

    Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

    Mechanism of action
    Further information: Serotonin receptor agonist and Triptan § Mechanism_of_action

    Frovatriptan is a 5HT receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites.

    Adverse effects

    Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

    Contraindications

    Frovatriptan should not be given to patients with:

    • Ischemic heart disease
    • Cerebrovascular syndrome
    • Peripheral vascular disease
    • Uncontrolled hypertension
    • Hemiplegic or basilar migraine

    US licensing

    Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.[2]

    References
    1. "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
    2. "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.